(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 2.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Codexis's revenue in 2024 is $74,234,000.On average, 4 Wall Street analysts forecast CDXS's revenue for 2024 to be $4,751,347,235, with the lowest CDXS revenue forecast at $4,233,454,620, and the highest CDXS revenue forecast at $5,002,532,209. On average, 4 Wall Street analysts forecast CDXS's revenue for 2025 to be $4,459,944,442, with the lowest CDXS revenue forecast at $3,598,436,427, and the highest CDXS revenue forecast at $5,115,424,333.
In 2026, CDXS is forecast to generate $6,873,719,151 in revenue, with the lowest revenue forecast at $6,873,719,151 and the highest revenue forecast at $6,873,719,151.